Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Conversion therapy for advanced penile cancer with tislelizumab combined with chemotherapy: A case report and review of literature
Xiang-Yu Long, Shuang Zhang, Lian-Sha Tang, Xiang Li, Ji-Yan Liu
Xiang-Yu Long, Department of Oncology, Guang’an People’s Hospital, Guang’an 638500, Sichuan Province, China
Xiang-Yu Long, Department of Biotherapy, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China
Shuang Zhang, Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Lian-Sha Tang, Ji-Yan Liu, Department of Biotherapy, Sichuan University, Chengdu 610041, Sichuan Province, China
Xiang Li, Department of Urology, West China Medical School, Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Long XY and Liu JY conceived and designed the project; Long XY, Zhang S and Li X were responsible for the sample collection; Long X and Liu JY wrote the manuscript and are responsible for all data present in current research.
Supported by the Key Research and Development Program of Guang’an, China, No. 2019ZYZF0121.
Informed consent statement: Consent was obtained from the patient for publication of this report.
Conflict-of-interest statement: All the authors have stated that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
https://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Xiang-Yu Long, MA, Adjunct Associate Professor, Department of Oncology, Guang’an People’s Hospital, No. 1 Section 4, Binhe Road, Guang’an 638500, Sichuan Province, China. 371256871@qq.com
Received: June 18, 2022
Peer-review started: June 18, 2022
First decision: September 5, 2022
Revised: September 15, 2022
Accepted: October 26, 2022
Article in press: October 26, 2022
Published online: November 26, 2022
BACKGROUND
Locally advanced penile squamous cell carcinoma with unresectable inguinal lymph node metastasis has a poor prognosis, and surgical treatment alone offers limited benefits. Effective conversion therapy regimens are urgently needed.
CASE SUMMARY
We describe a locally advanced penile squamous cell carcinoma patient with bulky, fixed inguinal lymph node metastasis complicated with genital skin ulcers who underwent inguinal lymph node dissection and achieved a pathological complete response with conversion therapy comprising immunotherapy plus chemotherapy.
CONCLUSION
For unresectable locally advanced penile squamous cell carcinoma, neoadjuvant immunotherapy combined with chemotherapy is a potential treatment approach. Biomarkers of immunotherapy efficacy need to be explored, and clinical trials are needed to test these strategies.
Core Tip: Locally advanced penile squamous cell carcinoma with bilateral inguinal lymph node metastases and extra-nodal extension does not respond well to surgical treatment alone, and the prognosis is very poor. In this study, the patient successfully completed inguinal lymph node dissection after conversion therapy of immunotherapy plus chemotherapy. This is the first patient with human papillomavirus 16+ unresectable locally advanced penile cancer treated with immunotherapy plus chemotherapy who eventually achieved a pathologically complete response.
